George Jay Goldsmith, a ten percent owner at COMPASS Pathways plc (NASDAQ:CMPS), has sold a significant portion of his holdings in a private transaction. On October 24, 2024, Goldsmith disposed of 776,565 ordinary shares, which may be represented by American Depositary Shares (ADSs), to Lars Wilde, a former co-founder of the company. The sale was executed at a nominal value per ordinary share, as part of previously disclosed call option agreements.
This transaction was part of a private sale agreement with Wilde, who exercised his option to purchase these shares from Goldsmith and Dr. Ekaterina Malievskaia, Goldsmith's spouse, who also sold 776,565 shares under similar terms. Following these transactions, Goldsmith retains ownership of 3,155,122 shares, while Dr. Malievskaia holds 3,152,848 shares. The couple has explicitly disclaimed beneficial ownership of each other's shares in the company.
In other recent news, Compass Pathways has made substantial progress in its ongoing COMP360 Phase 3 clinical trials for treatment-resistant depression (TRD). The recent developments include the appointment of Lori Englebert as Chief Commercial Officer and Gino Santini as the new Chairman of the Board of Directors. TD Cowen has maintained its Buy rating on Compass Pathways, emphasizing the distinction between the company's research and the recent issues faced by Lykos Pharmaceuticals. The analyst from TD Cowen assured that the concerns raised for Lykos should not be indicative of potential problems for Compass Pathways. Compass Pathways also reported using $34.4 million in operations during the quarter, with sufficient funds to continue operations into 2026. The company is currently exploring the potential of psilocybin therapy for post-traumatic stress disorder (PTSD), deeming it a higher priority than bipolar disorder. Lastly, Compass Pathways expects to release primary endpoint data by the end of the year and follow-up data in the middle of the next year.
InvestingPro Insights
As George Jay Goldsmith and Dr. Ekaterina Malievskaia reduce their stakes in COMPASS Pathways plc (NASDAQ:CMPS), investors may be curious about the company's financial health and market performance. According to InvestingPro data, COMPASS Pathways has a market capitalization of $439.74 million, reflecting its current valuation in the biotech sector.
The company's financial position shows some strengths and challenges. An InvestingPro Tip highlights that COMPASS Pathways holds more cash than debt on its balance sheet, which could provide financial flexibility as it pursues its research and development initiatives. This is particularly important given another InvestingPro Tip indicating that the company is quickly burning through cash, a common characteristic of biotech firms in the development stage.
COMPASS Pathways' stock performance has been mixed, with a one-year price total return of 12.61% as of the latest data. However, the year-to-date return stands at -26.51%, suggesting recent headwinds. The stock is currently trading at 50.43% of its 52-week high, which may interest value investors looking for potential entry points.
It's worth noting that analysts do not anticipate the company to be profitable this year, as per an InvestingPro Tip. This aligns with the reported adjusted operating income of -$141.51 million for the last twelve months as of Q2 2024, underscoring the company's focus on research and development rather than immediate profitability.
For investors seeking a more comprehensive analysis, InvestingPro offers additional insights with 8 more tips available for COMPASS Pathways, which could provide a deeper understanding of the company's prospects and challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.